We also explored the relationship between p16 and survival of breast cancer patients by survival analysis and the results elaborated that breast cancer patients with high expression of p16 (alias: CDKN2A) had a higher survival rate (hazard ratio = 1.18, p-value = 0.0012) (Fig. 4A). This evidence concerns the gene CDKN2A and breast cancer.